Product Images Doxazosin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Doxazosin NDC 43353-648 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Bottle Label 2mg - 43353 647

Bottle Label 2mg - 43353 647

Doxazosin Mesylate is a medication available in tablet form, with 90 tablets per container, each containing 2mg of the active ingredient. The tablets should be kept in a place where the temperature is between 20 and 25 degrees Celsius, and should be kept away from the reach of children. The manufacturer of the medication is Mylan Pharmaceuticals Inc, based in Morgantown, WV, and it was repackaged by Aphena Pharma in Cookeville, TN. The batch number for this medication is N 43353-0647-60.*

Bottle Label 4mg - 43353 648

Bottle Label 4mg - 43353 648

This is a description of a medication called Doxazosin Mesylate. It comes in a package of 90 tablets and is manufactured by Mylan Pharmaceuticals Inc in Morgan town, WV. It has a batch number of 2 and a lot number of 43353-0648-60. The medication should be stored between 20-25 degrees Celsius and kept out of reach of children. It should also be dispersed in its original container, which is certified by USP standards. The medication is re-packaged by Aphena Pharma in Cookesville, TN 38506.*

Aphena Pharma Solutions - TN - Aphena

Aphena Pharma Solutions - TN - Aphena

Structural Formula - a7293678 9b1b 4102 9a79 1000d853dc16 01

Structural Formula - a7293678 9b1b 4102 9a79 1000d853dc16 01

Figure 1 - a7293678 9b1b 4102 9a79 1000d853dc16 02

Figure 1 - a7293678 9b1b 4102 9a79 1000d853dc16 02

This appears to be a figure or graph depicting the mean change in total symptom score and mean increase in maximum urinary flow rate from baseline over a duration of treatment in weeks. No further information or context is available.*

Table 1 - a7293678 9b1b 4102 9a79 1000d853dc16 03

Table 1 - a7293678 9b1b 4102 9a79 1000d853dc16 03

This appears to be a tabular presentation of data from three studies involving the use of doxazosin to treat hypertension associated with benign prostatic hypertrophy (BPH). The studies involved titration to maximum dose, titration to fixed dose for 14 weeks, and titration to fixed dose for 12 weeks, respectively. The effectiveness of treatment was evaluated using the maximum flow rate and symptom score of patients. The fourth column contains numerical values for mean baseline and baseline change. The output shows some inaccuracies in the numbers making it difficult to draw precise conclusions.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.